· Executive Brief
World Hypophosphatasia Day 2026
Move from isolated campaign activity to one connected operating plan across internal and community partners.
Leadership signal
Use World Hypophosphatasia Day to examine the system behind the message.
A public-facing observance can involve communications, operations, service lines, community partners, and leadership. Before publishing activity, align the message with real routes, available support, ownership, escalation, and the method used to answer questions that the campaign may generate.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
A rare disease that hides inside routine laboratory results
Hypophosphatasia is a rare inherited disorder of bone and tooth mineralization. Its defining laboratory clue, a low alkaline phosphatase value, already appears in many routine chemistry panels. The executive problem is not whether the signal exists. It is whether anyone in the organization notices it, owns it and moves the patient toward the right expertise. Because the condition is rare and its symptoms overlap with common complaints, recognition rarely happens by chance. It happens when a system is designed to look.
The evidence suggests that recognition is the weak link. A systematic review estimated that general-population prevalence may be 17.6 to 36.0 per 100,000, based on three studies that met all four quality criteria.[1] Among patients with persistently low alkaline phosphatase, genetically confirmed hypophosphatasia ranged from 10.4% to 26.2% in general clinical populations.[1] Those findings mean a health system of any size is likely to have unrecognized patients in its own records.
Delay is common once symptoms begin. In a global hypophosphatasia registry, adults had a median age of 37.6 years at earliest reported manifestation and 47.5 years at diagnosis, a gap of about 10 years.[15] Across rare diseases more broadly, a survey of 6,507 people in 41 European countries found an average total diagnosis time of 4.7 years.[13]
World Hypophosphatasia Day is a useful moment to examine that gap as an operating question. The sections below summarize current peer-reviewed evidence on recognition, referral, coordination, equity, workforce readiness and communication. They sit beside the executive guidance already on this page and give leaders a shared factual base for deciding where one improvement would matter most. The aim is practical: fewer patients who wait a decade for a name, and fewer families who carry the coordination burden alone.
Current evidence
The signal is common in records, and recognition lags behind it
The yield of looking for hypophosphatasia depends heavily on where an organization looks. In the systematic review, 710 articles were retrieved and 27 met inclusion criteria.[1] Among patients with persistently low alkaline phosphatase, confirmed hypophosphatasia was 46.4% to 56.5% in rheumatology populations and 57.1% to 87.5% in osteoporosis populations.[1] Those service lines see adults whose bone and joint complaints can resemble more common conditions.
Systematic laboratory surveillance can surface patients who would otherwise remain unseen. A Chinese pediatric program screened the laboratory records of 178,778 children from September 2023 through August 2025 using daily surveillance.[2] Children with persistently low values below the 2.5th percentile for age and sex underwent genetic sequencing.[2] Among 339 enrolled children, the program confirmed hypophosphatasia in 32, identified 25 suspected cases and found 57 asymptomatic carriers.[2] Across the enrolled group, 73 clinically relevant variants were identified in 114 individuals, and functional assays supported reclassifying three variants of uncertain significance as likely pathogenic.[2] The program shows what a defined threshold, a daily review and a testing route can produce at scale.
Adult hospital data tell a similar story. An adult maximum care provider reviewed 15 years of results below 21 U/L and distinguished 88 patients with temporary low values from 20 with persistent low values who were re-examined.[10] Genetic analysis in 12 patients with persistent low values identified a pathogenic variant in 11.[10] A model built from routine laboratory values separated the two groups with an accuracy of 90% and an area under the curve of 0.94.[10]
The clinical burden is substantial once the condition is recognized. In a Spanish registry cohort of 83 patients, the median time to diagnosis was 4.8 years, with a range from 0 to 49.9 years.[8] Among adults, pain was the most frequent symptom, reported by 64.2%, and 23.7% had symptoms that began before age 18.[8] In five Central and Eastern European countries, 33 of 34 patients with detailed data (97%) had enzyme levels below the reference range, and 25 (73%) reported chronic musculoskeletal pain.[4]
Measurement itself is uneven. A decade of global registry data showed that pyridoxal 5′-phosphate testing was performed in 18% to 61% of registry patients across geographic regions.[7] Phosphoethanolamine testing ranged from 5% to 48%.[7] For executives, that variation is a governance signal. Diagnostic practice for the same condition differs widely depending on where a patient happens to receive care.
Figure 1
Diagnosis takes years for rare diseases, and longer for adults with hypophosphatasia
Years from first symptom or first medical contact to diagnosis, as reported in each study. Values are copied from the cited studies [8], [13], [15]; none is estimated.
Data note. Indirect comparison: the values come from three different studies with different populations, definitions and statistics (one mean, one median, one gap between median ages), so they show the scale of delay rather than a ranking.
Limitation. Survey and registry data rely on reported dates of first symptoms or contact; the adult registry gap is stated by its authors as approximate and the registry data predate 2018.
Figure data (3 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Average total diagnosis time, people with a rare disease | 4.7% | Mean; 6,507 survey respondents living with 1,675 rare diseases in 41 European countries | [13] |
| Median time to diagnosis, hypophosphatasia cohort | 4.8% | Median (range 0 to 49.9 years); 83 patients in the Spanish cohort of a global hypophosphatasia registry | [8] |
| Gap from earliest manifestation to diagnosis, adults with hypophosphatasia | 10% | Reported as about 10 years (median age 37.6 years at earliest manifestation and 47.5 years at diagnosis); 148 adults in a global registry enrolled 2015 to 2017 | [15] |
Continuum of care
From an abnormal value to a coordinated care plan
The care continuum for hypophosphatasia begins long before a specialist visit. It starts when a result is reported, continues when a clinician interprets it, and depends on a referral that someone must accept. Registry data show how long that chain can take. Children in the global registry had a median age of 7.2 months at earliest manifestation, which was more than 12 months before diagnosis at 20.4 months.[15] Every month in that interval is a period in which a result existed but a pathway did not.
Adults often reach specialists through other service lines first. In the same registry, the most common adult history items were pain (74.5%), orthopedic procedures and therapies (44.6%) and recurrent or poorly healing fractures (36.5%).[15] In the Central and Eastern European cohort, tooth loss, fractures and bone deformities were seen in 26%, 44% and 18% of patients, respectively.[4] Dental, orthopedic, rheumatology and bone health teams therefore sit on the pathway, whether or not they are named in it.
Recognition does not guarantee follow-through. In the Central and Eastern European cohort, only one patient received treatment with asfotase alfa.[4] That finding does not establish who should be treated. It does show that confirmation of a diagnosis and access to specialist management are separate steps that leaders should track separately.
Patients describe the handoffs as the hardest part. In a German mixed-methods study of 299 participants, including 176 patients and 123 caregivers of pediatric patients, most reported receiving written information about their care.[14] Interviews with 50 participants nevertheless revealed experiences of uncoordinated care, low engagement and communication difficulties between sectors.[14] The authors concluded that intersectoral collaboration should go beyond written information exchange and relieve patients of feeling responsible for communication between sectors.[14]
That conclusion reframes the continuum for executives. A referral letter is a transfer of paper, not a transfer of responsibility. The executive guidance on this page addresses acknowledgment and ownership. The evidence adds that, for rare conditions, patients and families too often become the coordinators by default. A reliable continuum for a rare condition has three features. A result is linked to a named reviewer. A referral is accepted by a team with relevant expertise. A care plan is shared with every service that will see the patient again, including dental, orthopedic and primary care teams.
Figure 3
Why the pathway breaks
People
- Clinicians report insufficient rare disease knowledge
- Patients and families left to coordinate between sectors
- Limited genetic counseling support for follow-up
Process
- No owner for persistently low results
- Referral routes differ by service line
- Pediatric and adult services restart the diagnostic process
Technology
- No laboratory surveillance or flag for persistent low values
- Decision support tools with limited rare disease accuracy
- Clinicians lack access to shared records
Environment
- Expertise concentrated in few centers
- Symptoms seen first in dental, orthopedic or rheumatology settings
- Many consultations before diagnosis
Policy
- Unmet psychological and financial support needs
- Economic hardship and language barriers limit referral and application
- No defined pathway to specialist management
Measurement
- Diagnostic delay not measured locally
- Confirmatory testing varies widely by region
- Referral and completion not stratified by language or payer
Unranked qualitative cause-and-effect diagram for the outcome in the box: Persistently low alkaline phosphatase results and suggestive symptoms do not lead to timely recognition, specialist referral and coordinated care for hypophosphatasia Causes are assembled from the cited literature [2], [3], [4], [5], [6], [7], [9], [10], [11], [12], [13], [14]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Clinicians report insufficient rare disease knowledge; Patients and families left to coordinate between sectors; Limited genetic counseling support for follow-up |
| Process | No owner for persistently low results; Referral routes differ by service line; Pediatric and adult services restart the diagnostic process |
| Technology | No laboratory surveillance or flag for persistent low values; Decision support tools with limited rare disease accuracy; Clinicians lack access to shared records |
| Environment | Expertise concentrated in few centers; Symptoms seen first in dental, orthopedic or rheumatology settings; Many consultations before diagnosis |
| Policy | Unmet psychological and financial support needs; Economic hardship and language barriers limit referral and application; No defined pathway to specialist management |
| Measurement | Diagnostic delay not measured locally; Confirmatory testing varies widely by region; Referral and completion not stratified by language or payer |
Access
Access depends on reaching expertise, not only on getting an appointment
Access to rare disease care is mostly access to the right expertise at the right time. In a Swedish survey of 942 respondents representing 120 diagnoses, more than one third were diagnosed within six months of first healthcare contact and nearly half within one year.[3] One in ten waited more than ten years.[3] Seven out of ten had consulted an expert in their condition.[3]
Those with the longest waits had the weakest access to expertise. Respondents with diagnostic delays exceeding ten years were less likely to see a specialist.[3] They were also more likely to perceive unmet healthcare needs.[3] Delay and specialist access appear to travel together, which is why referral routes deserve executive attention rather than case-by-case rescue. For a rare bone disorder, a decade of delay can mean years of pain, procedures and fractures before the underlying cause is named.
The European survey points to the same operational drivers. Fifty-six percent of respondents were diagnosed more than six months after a first medical contact.[13] Determinants of longer delay included symptom onset in childhood or adolescence, being a woman, consulting many healthcare professionals, misdiagnosis, and unmet psychological or financial support needs.[13] Several of those factors are features of how care is organized rather than features of the disease.
Patients and carers also say what access means to them. A discrete choice experiment with 996 respondents, including 528 patients, 280 carers and 188 health care professionals, examined preferences for coordinated rare disease care.[12] All six attributes, including clinical expertise, specialist centers and appointment costs, significantly influenced which service respondents preferred.[12] Patients and carers favored services that gave them more autonomy in relation to the role of care coordinators.[12] Those preferences suggest that families weigh expertise, coordination and cost together rather than any single feature.
For a rare bone condition, few organizations will host every needed specialty under one roof. The access question for leaders is therefore whether a defined route exists to an external or internal center with relevant expertise. That route should work regardless of which service line first sees the abnormal result or the symptomatic patient. Leaders can test that route directly. Pick a recent persistently low result and trace whether it led to a documented decision, an accepted referral and a first specialist contact. Where the trace stops is where access is failing.
Executive guidance · System route
Connect the day to an accountable system route.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Define the purpose
- Align the entry point
- Coordinate the partner route
- Manage response
- Review the campaign
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Define the purpose
Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise.
Align the entry point
Connect every communication channel to current information and a clearly identified receiving role or team.
Coordinate the partner route
Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.
Manage response
Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them.
Review the campaign
Compare intended action with local process signals and partner feedback, then document the improvement to carry forward.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Define the purpose | Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise. |
| Align the entry point | Connect every communication channel to current information and a clearly identified receiving role or team. |
| Coordinate the partner route | Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal. |
| Manage response | Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them. |
| Review the campaign | Compare intended action with local process signals and partner feedback, then document the improvement to carry forward. |
Equity and trust
Who reaches a diagnosis, and who loses trust along the way
Rare disease pathways can widen gaps if access to expert evaluation depends on persistence, language or resources. A retrospective review of 2,235 participants in a national undiagnosed disease network from 2015 to 2023 examined whether the program reached historically marginalized groups.[11] Hispanic and Black non-Hispanic participants were underrepresented compared with the U.S. population, and participants whose primary language was not English were significantly underrepresented.[11] The authors noted that rare diseases affect 6% to 8% of the population.[11] Small gaps at entry can therefore add up across a large group of people.
The same study found that diagnosis was achievable across groups once people entered evaluation. Diagnosis rates were highest among Asian non-Hispanic (39.5%) and Hispanic (35.3%) participants and lowest among White non-Hispanic participants (26.8%).[11] After adjustment, only participant age and disease phenotype predicted receiving a diagnosis.[11] The authors linked participation gaps to differences in application rates, possibly driven by economic hardship and language barriers.[11]
That pattern matters for executives. It suggests the equity risk lies at the front door, in who is referred and who completes an application, rather than in what expert teams can do once a patient arrives. Measuring referral and completion by language, payer and geography is one way to see that front-door gap locally. Front-door measures are also cheaper to collect than outcome measures. Referral counts, application completion and missed appointments already exist in most scheduling and referral systems.
Trust erodes when delays stretch on. In the Swedish survey, respondents whose diagnosis took more than ten years reported lower trust in healthcare and in healthcare professionals.[3] The European survey identified misdiagnosis and unmet psychological or financial support needs among the determinants of delay.[13] Each additional unexplained visit can cost an organization credibility with the patient and family it is trying to help. For many families, the experience of being doubted lasts longer than the delay itself.
Sex and age at onset also shape the experience. Being a woman and symptom onset in childhood or adolescence were associated with longer diagnostic delay across rare diseases.[13] In the Spanish hypophosphatasia cohort, 23.7% of adults had symptoms that began before age 18.[8] Leaders can ask whether pediatric and adult services share information well enough to avoid restarting the diagnostic process at transition. A transition plan that carries forward prior results, imaging and genetic findings protects both continuity and trust.
Human infrastructure
Clinicians, laboratories and coordinators carry the pathway
Rare disease recognition depends on clinicians who may see one case in a career. A single-center study surveyed 218 Chinese emergency physicians between April and June 2023, of whom 108 had received rare disease continuing education and 110 had not.[9] Most respondents (98.2%) felt their knowledge about rare diseases was insufficient.[9] The authors concluded that emergency physicians generally lacked rare disease knowledge and that continuing education can improve awareness and knowledge.[9]
Education alone cannot carry a condition this rare. Laboratory professionals and informatics teams are part of the human infrastructure. The pediatric surveillance program depended on daily review of results and a defined threshold for further testing.[2] The adult hospital analysis showed that routine laboratory values could help separate temporary from persistent low results.[10] Both designs place recognition in a system rather than in one clinician’s memory. That shift matters for staffing. It turns a rare event into a routine task with a defined owner, a threshold and a time standard, which is easier to train for and easier to audit.
Decision support tools can help, but their limits should be understood. A benchmark of 5,213 published case reports tested seven large language models against an established rare disease decision support tool.[6] The best language model ranked the correct diagnosis first in 23.6% of cases, compared with 35.5% for the established tool.[6] Leaders evaluating new tools should ask for performance evidence in rare conditions rather than assuming general accuracy will transfer.
Coordination is also a workforce role. Health care professionals in the discrete choice experiment expressed a stronger preference than patients and carers for a documented formal emergency plan.[12] Those preferences describe the information and coordination support frontline teams need to manage rare conditions safely across settings. Record access and emergency planning are infrastructure decisions, not individual clinician tasks.
Genetic counseling capacity is part of the same picture. In a study of hypophosphatasia carriers identified through carrier screening, 83.3% of 30 respondents were glad the condition was included.[5] Participants completed a mean of 5.13 of 18 follow-up actions (28.5%).[5] Counseling began the process, but sustained follow-through required more support than a single conversation. Leaders can ask whether genetic counselors, nurse coordinators or navigators have protected time for these follow-up conversations, and whether that work is visible in staffing plans.
Executive guidance · Operating dashboard
Review reliability, not campaign activity alone.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Message alignment
Do channels and partners communicate one current and appropriately bounded route?
- Candidate local measure
- Content review status, conflicting instructions, corrections, and unresolved questions.
Executive guidance · Signal
Response ownership
Does every campaign-generated request reach an accountable receiver?
- Candidate local measure
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
Executive guidance · Signal
Partner-route reliability
Do participating teams share one current route and understand who owns each dependency?
- Candidate local measure
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Executive guidance · Signal
Action closure
Did leaders complete and verify the improvement selected for the campaign window?
- Candidate local measure
- Assigned action, status, evidence of completion, and post-action review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Message alignment | Executive sponsor and operational lead |
| Response ownership | Operational owner and participating teams |
| Partner-route reliability | Sending and receiving owners |
| Action closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Transfer responsibility with acknowledgment and visibility.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the sending and receiving owners, shared information, current status, and unresolved dependency.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Connect operating signals to accountable executive review.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Message alignment | Do channels and partners communicate one current and appropriately bounded route? | Executive sponsor and operational lead | At campaign launch and close |
| Response ownership | Does every campaign-generated request reach an accountable receiver? | Operational owner and participating teams | At a locally defined cadence |
| Partner-route reliability | Do participating teams share one current route and understand who owns each dependency? | Sending and receiving owners | At a locally defined cadence |
| Action closure | Did leaders complete and verify the improvement selected for the campaign window? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable recognition-to-care pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Defined rule for persistently low alkaline phosphatase results | Low values are reported but never acted on, and patients remain undiagnosed for years | Laboratory medical director with chief medical information officer | Documented rule, flag in the record and periodic review of flagged results |
| Named owner for each flagged result | Results move between teams without anyone accepting the next step | Primary care and specialty medical directors | Share of flagged results with a documented decision by a named clinician |
| Single referral route to hypophosphatasia expertise | Each service line improvises, and long delays cluster among patients who never reach a specialist | Chief medical officer with service line leaders | Published route, accepting center and referral acknowledgment time |
| Shared care plan and record access across settings | Patients carry information between sectors and receive uncoordinated care | Care coordination lead | Share of confirmed patients with a care plan accessible to all treating teams |
| Follow-up support after genetic results | Families complete few follow-up actions after counseling | Genetic counseling program lead | Completion of agreed follow-up actions at a locally defined interval |
| Equity review of referral and completion | Participation gaps by language and economic hardship stay invisible | Health equity officer with quality leadership | Referral and completion stratified by language, payer, geography and sex |
| Diagnostic delay reported to governance | Delay is accepted as normal and never improves | Chief quality officer and board quality committee | Locally measured time from first flagged result to diagnosis, reviewed on a set cadence |
Control points derived from the cited evidence [2], [3], [5], [7], [10], [11], [12], [13], [14] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Clear messages about a condition few people have heard of
Public communication about hypophosphatasia faces a basic challenge. Most patients, families and many clinicians have never heard the name. Campaign messages therefore work best when they connect a recognizable experience, such as unexplained bone pain, early tooth loss or repeated fractures, to a clear and accurate next step through approved channels. Internal communication matters as much as public messaging. Laboratory, primary care and specialty teams need the same plain description of what a persistently low result means operationally and who receives it.
The evidence shows why accuracy and restraint matter. Registry data describe pain, fractures, dental problems and orthopedic procedures among common manifestations.[15] Many of those complaints are also familiar from more common conditions. Messages that imply every such symptom signals a rare disease could generate anxiety and demand that the route is not designed to absorb. Messages can instead describe the route: where a question goes, who answers it and what happens after a result is reviewed.
Communication after a result is as important as communication before it. In the carrier screening study, participants who felt their results were burdensome reported lower satisfaction, and follow-up actions were often incomplete.[5] Messages for families who learn they carry a variant need plain explanations, defined next steps and a named point of contact. Those contacts should be able to explain what the result means for relatives, what remains uncertain and which actions are optional rather than urgent.
Patients also judge communication by what happens between teams. The German study found that written information did not prevent experiences of uncoordinated care and communication difficulties between sectors.[14] Public messages that promise coordinated support should reflect a route that actually works across primary care, specialty services and laboratories. Before launch, leaders can ask each named team to confirm it will receive the questions a message may generate.
Trust is the outcome to protect. Long diagnostic journeys were linked to lower trust in healthcare and healthcare professionals in the Swedish survey.[3] Registry authors concluded that a decade of real-world learning may play an important role in improving disease recognition and diagnosis.[7] World Hypophosphatasia Day communications can support that goal when they are honest about uncertainty and specific about where people can turn. A modest, accurate message that leads to a working route will do more for patients than a broad message that leads nowhere.
Executive guidance · 90-day plan
Use 90 days to correct one visible operating barrier.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how World Hypophosphatasia Day communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how World Hypophosphatasia Day communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Pair recognition with a system people can trust.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Connect the message to one usable, measured, and sustained operating change.
Executive action kit · Day observance
Turn World Hypophosphatasia Day into accountable action.
Move from isolated campaign activity to one connected operating plan across internal and community partners.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, coordination, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review language, disability, transportation, digital access, geography, trust, and other barriers using protected feedback and locally appropriate data.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, frontline teams, operational leaders, and community partners. Find one a message, request, referral, or handoff that does not reach an accountable owner, then test the locally approved route from entry through acknowledged follow-through.
- Define the purpose
- Align the entry point
- Coordinate the partner route
- Manage response
- Review the campaign
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Content review status, conflicting instructions, corrections, and unresolved questions.
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During World Hypophosphatasia Day, our organization will connect awareness with a practical review of the information, access, coordination, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
World Hypophosphatasia Day is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Schäfer VS, Hinman J, Moss K, Charles JF, Adachi JD, Singer AJ, et al. Prevalence of hypophosphatasia in general and selected patient populations: a systematic review. Osteoporosis International. 2026:online ahead of print, October 7, 2026. https://doi.org/10.1007/s00198-026-08227-8
- 2.Zhang D, Wang X, Zhou L, Li Q, Wu H, Yang B, et al. Diagnostic Yield of Laboratory-Based Screening for Hypophosphatasia Among Chinese Children With Low Alkaline Phosphatase. The Journal of Clinical Endocrinology & Metabolism. 2026:dgag400 (online ahead of print, September 30, 2026). https://doi.org/10.1210/clinem/dgag400
- 3.Soller MJ, Luckhaus JL, Juran S, Malmgren CI. Diagnostic delay, care needs, and trust in healthcare among persons with rare disease and their next of kin living in Sweden. Journal of Community Genetics. 2026;17(5):102. https://doi.org/10.1007/s12687-026-00931-6
- 4.Kužma M, Payer J, Petrovič R, Bandura A, Szegedi M, Dzivite-Krišane I, et al. Prevalence of clinical manifestations among patients with hypophosphatasia in Central and Eastern European countries. Frontiers in Endocrinology. 2026;17:1892714. https://doi.org/10.3389/fendo.2026.1892714
- 5.Morris BX, Grinzaid KA, Rosen A, Gambello MJ, Long V, Hardy MW. Impacts of genetic counseling on hypophosphatasia heterozygotes identified through carrier screening. Journal of Genetic Counseling. 2026;35(3):e70245. https://doi.org/10.1002/jgc4.70245
- 6.Reese JT, Chimirri L, Bridges Y, Danis D, Caufield JH, Gargano MA, et al. Systematic benchmarking demonstrates large language models have not reached the diagnostic accuracy of traditional rare-disease decision support tools. European Journal of Human Genetics. 2026;34(4):498-504. https://doi.org/10.1038/s41431-026-02054-5
- 7.Kishnani PS, Seefried L, Ozono K, Martos-Moreno GÁ, Rockman-Greenberg C, Fowler D, et al. The Global Hypophosphatasia Registry: lessons learned from a decade of real-world data. Orphanet Journal of Rare Diseases. 2025;20(1):626. https://doi.org/10.1186/s13023-025-04129-w
- 8.Tornero C, Martos-Moreno GÁ, Guañabens N, Flórez H, Ribera A, Aguado P. Clinical characterization and impact of hypophosphatasia in Spain: An observational analysis of the Spanish cohort included in the Global HPP Registry. Medicina Clínica (English Edition). 2025;165(5):107120. https://doi.org/10.1016/j.medcle.2025.107120
- 9.Liu A, Hao W, Xu J, Zhu H, Yang H, Yang J. Effects of continuing medical education on emergency trainees’ rare disease knowledge and attitude: a single-center study. BMC Medical Education. 2025;25(1):545. https://doi.org/10.1186/s12909-025-07149-z
- 10.Hennings R, Le Duc D, Bundalian L, Tönjes A, Lemke JR, Thiery J, et al. Screening for Hypophosphatasia in Adult Patients at a Maximum Care Provider—Retrospective Analyses over Fifteen Years. Journal of Clinical Medicine. 2024;13(23):7313. https://doi.org/10.3390/jcm13237313
- 11.Borja NA, Tinker RJ, Bivona SA, Smith CA, Krijnse Locker T, Fernandes S, et al. Advancing Equity in Rare Disease Research: Insights From the Undiagnosed Disease Network. American Journal of Medical Genetics Part A. 2024;197(2):e63904. https://doi.org/10.1002/ajmg.a.63904
- 12.Morris S, Walton H, Simpson A, Leeson-Beevers K, Bloom L, Hunter A, et al. Preferences for coordinated care for rare diseases: discrete choice experiment. Orphanet Journal of Rare Diseases. 2024;19(1):332. https://doi.org/10.1186/s13023-024-03353-0
- 13.Faye F, Crocione C, Anido de Peña R, Bellagambi S, Escati Peñaloza L, Hunter A, et al. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey. European Journal of Human Genetics. 2024;32(9):1116-1126. https://doi.org/10.1038/s41431-024-01604-z
- 14.Inhestern L, Otto R, Brandt M, Zybarth D, Oheim R, Schüler H, et al. Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany – a mixed-methods study. Orphanet Journal of Rare Diseases. 2024;19(1):197. https://doi.org/10.1186/s13023-024-03207-9
- 15.Högler W, Langman C, Gomes da Silva H, Fang S, Linglart A, Ozono K, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskeletal Disorders. 2019;20(1):80. https://doi.org/10.1186/s12891-019-2420-8
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Prevalence of hypophosphatasia and yield among patients with persistently low alkaline phosphatase | [1] | 2026 | Current evidence | Systematic review of 27 heterogeneous studies; general-population estimate rests on three studies; yield ranges vary widely by population. |
| Laboratory-based surveillance and screening yield | [2] [10] | 2026, 2024 | Current evidence | Single-country pediatric program and a single adult hospital; genetic testing was performed in a subset of adults. |
| Diagnostic delay and clinical burden in hypophosphatasia registries and cohorts | [4] [8] [15] | 2026, 2025, 2019 | Current evidence | Registry and cross-sectional cohorts; small national samples; the global registry data were collected from 2015 to 2017. |
| Regional variation in confirmatory testing | [7] | 2025 | Current evidence | Registry-based review; testing rates reflect enrolled patients, not all patients with the condition. |
| Uncoordinated care and intersectoral communication | [14] | 2024 | Continuum of care | German mixed-methods study across several rare conditions; self-reported experience. |
| Diagnostic delay, specialist access and unmet needs across rare diseases | [3] [13] | 2026, 2024 | Access | Self-reported surveys in Sweden and Europe covering many diagnoses; not specific to hypophosphatasia. |
| Preferences for coordinated rare disease care | [12] | 2024 | Access | Discrete choice experiment with data collected in 2019; stated preferences rather than observed outcomes. |
| Representation and diagnosis rates by race, ethnicity and language | [11] | 2024 | Equity and trust | U.S. research network participants; findings may not reflect routine clinical care. |
| Clinician rare disease knowledge and continuing education | [9] | 2025 | Human infrastructure | Single-center survey of emergency physicians in China without pre-training data. |
| Performance of language models and decision support tools in rare disease diagnosis | [6] | 2026 | Human infrastructure | Benchmark built from published case reports rather than live clinical encounters. |
| Genetic counseling and follow-through after carrier results | [5] | 2026 | Public communication | Thirty survey respondents from one program; descriptive statistics. |
About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.